OR WAIT null SECS
Highlights from a wide ranging discussion on COVID-19 pandemic response from Kate Broderick, Chief Innovation Officer at Maravai LifeSciences, and Tom Madden, President & CEO at Acuitas Therapeutics.
Highlights from a wide ranging discussion on COVID-19 pandemic response, future government communications, and healthcare funding for mRNA with experts Dr. Kate Broderick, Chief Innovation Officer, Maravai LifeSciences, and Dr. Tom Madden, President & CEO, Acuitas Therapeutics.
Topics include supply chain modalities, ensuring a fully trained manufacturing workforce, combining delivery with gene editing innovations, epigenetic approaches to modulate gene expression moving toward the clinic. We conclude with the huge potential for RNA expression of monoclonal antibodies and protein replacement applications.
Catch the full podcast episode featuring Broderick and Madden when it goes live at the Drug Solutions soundcloud page.
Dr. Kate Broderick is Chief Innovation Officer at at TriLink Biotechnologies, a Maravai LifeSciences company. Prior to joining TriLink, Kate spent 15 years with Inovio Pharmaceuticals where she assumed positions of increasing responsibility, starting as Scientist, to her most recent position as Senior Vice President, R&D. She received her B.Sc. in Genetics and her Ph.D. in Molecular Genetics from the University of Glasgow.
Dr. Tom Madden is President & CEO at Acuitas Therapeutics. A world-renowned expert in the area of nanotechnology. Dr. Madden co-founded Acuitas Therapeutics in February 2009 and has guided the company into its position as a global leader through the development and application of lipid nanoparticle (LNP) technology. Dr. Madden obtained his BSc. and Ph.D. in Biochemistry from the University of London, U.K.